HomeAnalysisPharma Manufacturing Gains Expose Hyderabad’s Next Industrial Challenge

Pharma Manufacturing Gains Expose Hyderabad’s Next Industrial Challenge

The latest assessment of India’s production-linked incentive (PLI) schemes shows that pharmaceutical manufacturing has gained investment, production, employment and export momentum, but it also exposes a less comfortable reality for Hyderabad: scale alone will not determine which parts of the city’s life-sciences ecosystem capture the next phase of growth.

The assessment, published by NITI Aayog in partnership with IIM Ahmedabad, found that the pharmaceuticals drugs scheme, with an outlay of ₹15,000 crore, has delivered positive outcomes across its principal targets. The bulk-drugs scheme, supported by an outlay of ₹6,940 crore, enabled first-time domestic manufacturing of 191 bulk drugs. Yet its gains were uneven across product categories, and the report identified continuing vulnerabilities in some segments.

That distinction matters for Hyderabad because the city is not simply a location for pharmaceutical factories. It is a major hub of pharmaceutical and life-sciences companies, research institutions and manufacturing units. Its industrial future therefore depends on how effectively manufacturing incentives connect with research capacity, specialised production, employment and domestic value addition.

The assessment’s central finding is that the PLI model has been more effective for some participants and product categories than others. Large pharmaceutical firms recorded the strongest performance, supported by scale and global market integration. Mid-sized firms improved steadily, while micro, small and medium enterprises faced uneven outcomes, particularly in exports, because of constraints related to scale and market access.

This is an important qualification to the headline investment story. Investment consistently exceeded targets, while production and employment grew significantly. But a rise in aggregate output does not automatically mean that the entire industrial base is becoming more resilient. The distribution of gains across firm sizes and manufacturing segments determines whether the policy builds a broad ecosystem or primarily strengthens its largest participants.

For cities such as Hyderabad, that distribution has practical consequences. A manufacturing system with strong large companies but weaker smaller suppliers may generate investment without creating equivalent depth across the wider industrial network. The supplied assessment does not quantify the local employment impact for Hyderabad or provide a city-level breakdown of investments. It does, however, identify the structural conditions that will shape the city’s ability to benefit from national pharmaceutical policy.

The bulk-drugs results are especially revealing. Chemical synthesis-based key starting materials, drug intermediates and active pharmaceutical ingredients emerged as the strongest performers. Segment I drugs, covering key fermentation-based starting materials and drug intermediates, recorded a late but sharp production scale-up. Segment II drugs, consisting of niche fermentation-based starting materials, intermediates and APIs, grew gradually from a low base.

Segment III drugs, which include key chemical synthesis-based starting materials and intermediates, remained vulnerable across indicators. This uneven performance shows that “domestic manufacturing” is not a single achievement. Different products require different capabilities, investment horizons and routes to market. A scheme can create first-time production in several categories while still leaving weaknesses in strategically important segments.

That matters because bulk drugs and APIs sit upstream of finished pharmaceutical products. The assessment does not claim that India has eliminated dependence on imported inputs, and it does not establish the extent of Hyderabad’s import exposure. Industry representatives quoted in the report nevertheless said the city’s API, formulation and specialty-chemical base could benefit from greater domestic value addition and reduced dependence on imported inputs.

The policy question is therefore moving from whether incentives can attract investment to whether they can create durable industrial depth. The PLI schemes have helped push production and employment beyond targets, according to the assessment. The next test is whether that momentum reaches less integrated companies, vulnerable product categories and higher-value manufacturing capabilities.

For MSMEs, the reported export constraints are particularly significant. The assessment attributes uneven outcomes partly to limitations of scale and market access. Those are not only company-level problems. They affect the structure of the urban industrial ecosystem because smaller firms often participate as suppliers, specialist manufacturers and service providers around larger anchor companies. The supplied material does not provide data on the number or location of such firms in Hyderabad, but it establishes that firm size remains a major dividing line in the scheme’s outcomes.

The contrast with large pharmaceutical firms also reveals how global integration interacts with industrial policy. Large companies were able to record the strongest performance with the support of scale and global market integration. This suggests that incentives are most powerful when firms already possess the production capacity, market access and organisational reach to use them effectively. It also raises a policy implementation challenge: how to ensure that public support does not produce a narrow concentration of benefits.

The report’s findings point to a differentiated policy landscape rather than a uniform success-or-failure verdict. The pharmaceuticals drugs scheme and the bulk-drugs scheme have different outlays and have produced different results across manufacturing categories. The bulk-drugs scheme enabled domestic manufacturing of 191 drugs, but the performance of segments varied considerably. The evidence therefore supports a more precise assessment of policy outcomes: progress is substantial, but it is not evenly distributed.

For Hyderabad’s institutions and companies, the implications are also specific. Dr Ramchander Sharma, a Hyderabad-based pharma industry expert quoted in the report, said the city’s ecosystem was well placed to capture the next phase of India’s manufacturing growth. He added that companies should invest in green chemistry, continuous manufacturing and high-value APIs rather than compete only on volumes.

Those priorities connect industrial policy to the future shape of the city’s life-sciences economy. Green chemistry and continuous manufacturing are not merely technical choices in the supplied account; they represent a shift away from competing primarily through production volume. High-value APIs point towards greater value addition within the pharmaceutical chain. The assessment itself does not quantify the investment required for these transitions or identify which Hyderabad firms are pursuing them.

That evidence gap is important. The report establishes national-level scheme outcomes and identifies Hyderabad as a major relevant hub, but it does not establish a complete city-level account of land, utilities, logistics, environmental performance, housing pressure or worker mobility around pharmaceutical manufacturing. Nor does it specify how the reported gains are distributed across Hyderabad’s companies, industrial locations or workforce.

These limits do not reduce the significance of the findings. They clarify what the PLI assessment can and cannot show. It provides evidence that public incentives have supported investment, production and employment, and that domestic bulk-drug manufacturing has expanded into 191 products for the first time. It also shows that scale, export access and product category strongly influence performance.

The larger urban question is whether Hyderabad can convert sectoral growth into a deeper and more resilient city-region ecosystem. That depends on more than the number of factories or the value of incentives. It depends on whether smaller firms can access markets, whether vulnerable bulk-drug segments improve, and whether companies move into green chemistry, continuous manufacturing and high-value APIs.

The evidence currently confirms progress, not completion. Large firms are performing most strongly, mid-sized firms are improving, and MSME outcomes remain uneven. Bulk-drug manufacturing has expanded, but some categories remain vulnerable. The developments to monitor are therefore clear: whether the weaker segments improve, whether smaller firms gain market access, and whether Hyderabad’s pharmaceutical base captures more domestic value beyond volume-led production.


RELATED ARTICLES

Most Popular

Latest News